KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Work In Process (2016 - 2024)

Nektar Therapeutics has reported Work In Process over the past 12 years, most recently at $10.6 million for Q2 2024.

  • Quarterly results put Work In Process at $10.6 million for Q2 2024, changed N/A from a year ago — trailing twelve months through Jun 2024 was $10.6 million (changed N/A YoY), and the annual figure for FY2023 was $12.9 million, up 19.83%.
  • Work In Process for Q2 2024 was $10.6 million at Nektar Therapeutics, up from $10.0 million in the prior quarter.
  • Over the last five years, Work In Process for NKTR hit a ceiling of $12.9 million in Q4 2023 and a floor of $10.0 million in Q1 2024.
  • Median Work In Process over the past 3 years was $10.7 million (2022), compared with a mean of $11.3 million.
  • Peak annual rise in Work In Process hit 19.83% in 2023, while the deepest fall reached 19.83% in 2023.
  • Nektar Therapeutics' Work In Process stood at $10.7 million in 2022, then increased by 19.83% to $12.9 million in 2023, then dropped by 17.78% to $10.6 million in 2024.
  • The last three reported values for Work In Process were $10.6 million (Q2 2024), $10.0 million (Q1 2024), and $12.9 million (Q4 2023) per Business Quant data.